XIGDUO IR 10/500 TAB 28.S

About

XIGDUO IR 10/500 combines dapagliflozin and metformin immediate-release, offering a comprehensive approach to managing type 2 diabetes mellitus. Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces blood glucose by promoting its excretion in the urine. Metformin, a biguanide, primarily works by decreasing glucose production in the liver, reducing glucose absorption from the gut, and improving the body's sensitivity to insulin.

This combination therapy is indicated for adults with type 2 diabetes as an adjunct to diet and exercise, particularly when glycemic control is not adequately achieved with metformin alone or other antidiabetic agents. By targeting distinct mechanisms of glucose regulation, XIGDUO IR helps to lower both fasting and postprandial blood glucose levels. Dapagliflozin also provides additional benefits for cardiovascular and renal health in certain patient populations.

Uses

• Management of type 2 diabetes mellitus.
• Improvement of glycemic control in adults.
• Used as an adjunct to diet and exercise.
• When monotherapy is insufficient.

Directions For Use

Take this medication orally as directed by your physician, usually twice daily with meals to minimize gastrointestinal side effects.

Benefits

• Effectively lowers blood glucose levels.
• Provides cardiovascular benefits.
• Offers renal protective effects.
• May lead to modest weight loss.
• Reduces both fasting and postprandial glucose.
• Improves insulin sensitivity.

Side Effects

• Genital mycotic infections (yeast infections)
• Urinary tract infections
• Increased urination
• Nausea, diarrhea, abdominal pain
• Headache
• Dizziness
• Hypotension (low blood pressure)
• Dehydration
• Diabetic ketoacidosis (rare, serious)
• Lactic acidosis (rare, serious with metformin)
• Fournier's gangrene (very rare, serious)
• Vitamin B12 deficiency (long-term metformin use)

Safety Measures

• Alcohol - Excessive alcohol intake should be avoided as it can increase the risk of lactic acidosis, a rare but serious side effect, especially with metformin-containing products.
• Pregnancy - Not recommended during the second and third trimesters of pregnancy due to potential adverse effects on renal development. Consult a doctor; insulin is often preferred.
• Breastfeeding - It is not known if dapagliflozin is excreted in human milk, but metformin is. Use with caution and under medical supervision, weighing potential risks to the infant against maternal benefits.
• Liver - Use with caution in patients with hepatic impairment. Metformin is contraindicated in severe liver disease due to increased risk of lactic acidosis.
• Kidney - Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²). Dose adjustment or discontinuation may be required based on eGFR due to risks of metformin accumulation and reduced dapagliflozin efficacy.
• Lung - No specific contraindications related to lung conditions, but severe respiratory failure can increase lactic acidosis risk due to hypoxia.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.